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KEYWORDS	
	 A	series	of	benzisoxazole	derivatives	were	synthesized	and	evaluated	for	 their	antibacterial,
antioxidant	 and	 anti‐inflammatory	 activities.	 The	 results	 indicated	 that	 most	 of	 the
compounds	 exhibit	moderate	 antimicrobial	 activity	 against	 Gram	 negative	 (Escherichia	 coli,
Klebsiella	pneumoniae,	Salmonella	typhi,	Shigella	flexineri)	and	Gram	positive	(Bacillus	subtilis)
bacterial	culture.	The	molecules	were	evaluated	for	antioxidant	activities	using	2,2‐diphenyl‐
1‐picrylhydrazyl	scavenging,	super	oxide	radical	scavenging	and	hydroxyl	radical	scavenging
assays	and	most	of	them	showed	good	antioxidant	activities.	Also,	the	synthesized	compounds
were	 screened	 for	 anti‐inflammatory	 activities	 such	 as	 lipoxygenase	 inhibition	 and	 indirect
haemolytic	assays.	
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1.	Introduction	
	
Benzisoxazole	 derivatives	 are	 one	 of	 the	 most	 important	
heterocyclic	 system	 in	 the	 field	 of	 medicinal	 chemistry	 and	
associated	with	 the	wide	 range	of	biological	 activities	 such	as	
antimicrobial	 [1],	 anticonvulsant	 [2,3],	 antitumor	 [4,5],	 anti‐
psychotic	 [6‐8],	 antithrombotic	 [9]	 analgesic	 activities	 [10].	
They	have	also	exhibited	antiglycating	[11]	and	cholinesterase‐
inhibiting	properties	 [12‐13].	Previously	we	have	 investigated	
various	biological	 activities	 of	 these	benzisoxazole	derivatives	
as	 antimicrobial	 [1]	 and	 cholinesterase‐inhibiting	 agents	 [13].	
Recently,	we	have	also	reported	some	derivatives	of	piperidine	
conjugated	 benzisoxazole	 derivatives	 as	 antibacterial,	 anti‐
oxidant	 and	 anti‐inflammatory	 agents	 [14].	 In	 continuation	 of	
these	works,	we	extended	our	efforts	towards	the	synthesis	of	
new	 benzisoxazolylpiperidinesulfonyl	 derivatives	 and	 the	
study	of	 their	antibacterial,	antioxidant	and	anti‐inflammatory	
activities.	
	
2.	Experimental	
	
2.1.	Instrumentation	
	
The	 melting	 points	 were	 determined	 on	 Selaco	 melting	
point	 apparatus	 and	 are	 uncorrected.	 Infrared	 spectra	 were	
recorded	 on	 Shimadzu	 FT‐IR	model	 8300	 spectrophotometer.	
1H	 NMR	 spectra	 were	 recorded	 on	 an	 NMR	 spectrometer	
operating	 at	 400MHz	 using	 TMS	 as	 internal	 standard.	 Mass	
spectra	 were	 recorded	 using	 electrospray	 ionization	 mass	
spectrometry.	 The	 C,	 H	 and	N	 analysis	were	 performed	using	
CE‐400	CHN	analyzer.	Reactions	were	monitored	by	TLC	using	
pre‐coated	sheets	of	silica	gel	G/UV‐254	of	0.25	mm	thickness	
(Merck	 60F254)	 using	 UV	 light	 for	 visualization.	 All	 chemicals	
were	obtained	from	Aldrich,	Fluka	and	Merck	Chemicals.	
	
2.2.	Synthesis	
	
8‐Tert‐butyl	 4‐methyl	 3‐methyl‐2‐oxo‐1‐oxa‐8‐azaspiro	
[4.5]dec‐3‐ene‐4,8‐dicarboxylate	 (3),	 8‐(tert‐butoxycarbonyl)‐
3‐methyl‐2‐oxo‐1‐oxa‐8‐azaspiro[4.5]dec‐3‐ene‐4‐carboxylic	
acid	 (4),	 tert‐butyl	 4‐(4‐(6‐fluorobenzo[d]isoxazol‐3‐yl)piperi‐
dine‐1‐carbonyl)‐3‐methyl‐2‐oxo‐1‐oxa‐8‐azaspiro[4.5]dec‐
3‐ene‐8‐carboxylate	 (6),	 4‐(4‐(6‐fluorobenzo[d]isoxazol‐3‐yl)	
piperidine‐1‐carbonyl)‐3‐methyl‐1‐oxa‐8‐azaspiro[4.5]dec‐3‐
en‐2‐one	 hydrochloride	 (7)	 are	 synthesized	 according	 to	
reference	[14].	
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Table	1.	Derivatives	of	benzisoxazole.	
Entry	 R	(8,	9)	 Compound	 Yield	(%)	
1	 4‐MeC6H4	 9a 76
2	 2,5‐Cl2C6H3	 9b 71
3	 4‐MeOC6H4	 9c	 75	
4	 C6H5	 9d	 80	
5	 4‐FC6H4	 9e	 65	
6	 2‐NO2C6H4	 9f	 74	
7	 4‐NO2C6H4	 9g 68
8	 4‐ClC6H4	 9h 79
	
	
 
Reagents	and	reaction	conditions:	(a)	MeONa/THF,	0	°C‐RT,	8	h.	(b)	LiOH/MeOH/H2O,	0	°C‐RT,	3	h.	(c)	6‐fluoro‐3‐(piperidin‐4‐yl)benzo[d]isoxazole	
hydrochloride	5,	EDC.HCl/HOBt/DIPEA/CH2Cl2,	0	°C‐RT,	8h.	(d)	HCl/ether,	0	°C‐RT,	1h.	(e)	RSO2Cl	8,	TEA/EDC,	0	°C‐RT,	3‐4	h.	
	
Scheme	1
	
	
2.2.1.	General	procedure	for	the	synthesis	of	compounds	9a‐
h	
	
To	a	solution	of	compound	7	 (5	mmol)	and	triethyl	amine	
(5	mmol)	 in	 dichloromethane	 (20	mL);	 sulfonyl	 chloride	8	 (5	
mmol)	was	added	at	0	°C	and	stirred	at	room	temperature	for	
3‐4	h.	After	the	completion	of	the	reaction,	20	mL	of	water	was	
added	 and	 extracted	 the	 reaction	 mixture	 with	
dichloromethane	 (20	 mL	 ×	 2).	 The	 organic	 layer	 was	
concentrated	 under	 reduced	 pressure	 to	 get	 products	 9	
(Scheme	 1,	 Table	 1)	which	were	 purified	 by	 column	 chroma‐
tography	using	CHCl3:MeOH	(9:1,	v:v)	as	eluent.	
4‐(4‐(6‐Fluorobenzo[d]isoxazol‐3‐yl)piperidine‐1‐carbonyl)‐
3‐methyl‐8‐tosyl‐1‐oxa‐8‐azaspiro[4.5]dec‐3‐en‐2‐one	 (9a):	
Colour:	 White.	 Yield:	 76%.	 M.p.:	 104‐106	 °C.	 FT‐IR	 (KBr,	 ν,	
cm‐1):	1660	(Amide	CO	str.),	1740	(Ester	CO	str.),	3045	(Ar.	CH	
str.).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	8.09	(d,	2H,	J	=	7.8	Hz,	
Ar‐H),	7.78	(d,	2H,	J	=	8.2	Hz,	Ar‐H),	7.64	(d,	1H,	J	=	7.2	Hz,	Ar‐
H),	7.26	(d,	1H,	 J	=	7.2	Hz,	Ar‐H),	7.05	(s,	1H,	Ar‐H),	3.30‐3.39	
(m,	8H,	CH2),	2.75	(m,	1H,	CH),	2.54	(s,	3H,	CH3),	2.35	(S,	3H,	Ar‐
Me),	 1.65‐1.90	 (m,	 8H,	 CH2).	MS	 (ESI,	m/z):	 568	 (M+1).	 Anal.	
calcd.	 for	 C29H30FN3O6S:	 C,	 61.36;	 H,	 5.33;	 N,	 7.40.	 Found:	 C,	
61.41;	H,	5.39;	N,	7.47%.		
8‐((2,5‐Dichlorophenyl)sulfonyl)‐4‐(4‐(6‐fluorobenzo[d]iso	
xazol‐3‐yl)piperidine‐1‐carbonyl)‐3‐methyl‐1‐oxa‐8‐azaspiro	
[4.5]dec‐3‐en‐2‐one	(9b):	Colour:	White.	Yield:	71%.	M.p.:	110‐
112	°C.	FT‐IR	(KBr,	ν,	cm‐1):	1655	(Amide	CO	str.),	1756	(Ester	
CO	str.),	3049	(Ar.	CH	str.).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	
7.77	(s,	1H,	Ar‐H),	7.469‐7.55	(m,	3H,	Ar‐H),	7.28	(d,	1H,	J	=	7.8	
Hz,	Ar‐H),	7.03	 (s,	 1H,	Ar‐H),	3.25‐3.35	 (m,	8H,	CH2),	2.72	 (m,	
1H,	 CH),	 2.50	 (s,	 3H,	 CH3),	 1.62‐1.88	 (m,	 8H,	 CH2).	 MS	 (ESI,	
m/z):	623	(M+1).	Anal.	calcd.	 for	C28H26Cl2FN3O6S:	C,	54.02;	H,	
4.21;	N,	6.75.	Found:	C,	54.09;	H,	4.26;	N,	6.81%.		
4‐(4‐(6‐Fluorobenzo[d]isoxazol‐3‐yl)piperidine‐1‐carbonyl)‐
8‐((4‐methoxyphenyl)sulfonyl)‐3‐methyl‐1‐oxa‐8‐azaspiro[4.5]	
dec‐3‐en‐2‐one	 (9c):	 Colour:	White.	 Yield:	 75%	 (2.18	 g).	 M.p.:	
98‐100	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 1659	 (Amide	 CO	 str.),	 1782	
(Ester	CO	str.),	3047	(Ar.	CH	str.).	1H	NMR	(400	MHz,	CDCl3,	δ,	
ppm):	7.91	(d,	2H,	J	=	8.0	Hz,	Ar‐H),	7.56	(d,	1H,	J	=	7.6	Hz,	Ar‐
H),	 7.15‐7.24	 (m,	 3H,	 Ar‐H),	 6.97	 (s,	 1H,	 Ar‐H),	 3.82	 (s,	 3H,	
OMe),	 3.32‐3.45	 (m,	 8H,	 CH2),	 2.66	 (m,	 1H,	 CH),	 2.52	 (s,	 3H,	
CH3),	 1.62‐1.85	 (m,	 8H,	 CH2).	MS	 (ESI,	m/z):	 584	 (M+1).	Anal.	
calcd.	 for	 C29H30FN3O7S:	 C,	 59.68;	 H,	 5.18;	 N,	 7.20.	 Found:	 C,	
59.75;	H,	5.26;	N,	7.29%.		
4‐(4‐(6‐Fluorobenzo[d]isoxazol‐3‐yl)piperidine‐1‐carbonyl)‐
3‐methyl‐8‐(phenylsulfonyl)‐1‐oxa‐8‐azaspiro[4.5]dec‐3‐en‐2‐
one	 (9d):	 Colour:	 White.	 Yield:	 80%.	 M.p.:	 120‐122	 °C.	 FT‐IR	
(KBr,	ν,	cm‐1):	1659	(Amide	CO	str.),	1765	(Ester	CO	str.),	3055	
(Ar.	CH	str.).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	8.26	(s,	1H,	Ar‐
H),	8.04	(d,	1H,	J	=	7.8	Hz,	Ar‐H),	7.95	(d,	1H,	J	=	7.6	Hz,	Ar‐H),	
7.58	(m,	2H,	Ar‐H),	7.28	(m,	2H,	Ar‐H),	7.05	(s,	1H,	Ar‐H),	3.25‐
3.35	(m,	8H,	CH2),	2.70	(m,	1H,	CH),	2.52	(s,	3H,	CH3),	1.60‐1.84	
(m,	 8H,	 CH2).	 MS	 (ESI,	 m/z):	 554	 (M+1).	 Anal.	 calcd.	 for	
C28H28FN3O6S:	 C,	 60.75;	 H,	 5.10;	 N,	 7.59.	 Found:	 C,	 60.82;	 H,	
5.18;	N,	7.65%.		
4‐(4‐(6‐Fluorobenzo[d]isoxazol‐3‐yl)piperidine‐1‐carbonyl)‐
8‐((4‐fluorophenyl)sulfonyl)‐3‐methyl‐1‐oxa‐8‐azaspiro[4.5]dec‐
3‐en‐2‐one	 (9e):	 Colour:	White.	 Yield:	 65%.	M.p.:	 110‐112	 °C.	
FT‐IR	(KBr,	ν,	cm‐1):	1665	(Amide	CO	str.),	1755	(Ester	CO	str.),	
3068	(Ar.	CH	str.).		
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Table	2.	Antibacterial	activity	of	benzisoxazoles	9a‐h.	
Compound	 Zone	of	inhibition	in	millimetre	*	
Escherichia	coli Bacillus	subtilis Klebsiella	pneumoniae Salmonella	typhi	 Shigella	flexneri
9a	 11	 10	 11 10 ‐	
9b	 12	 ‐	 14 12 ‐	
9c	 12	 10	 12 12 ‐	
9d	 13	 10	 22 19 13	
9e	 11	 11	 16 18 ‐	
9f	 11	 13	 9 14 10	
9g	 11	 ‐	 10	 10	 ‐	
9h	 12	 10	 12	 11	 ‐	
*	Inhibition	zones	including	disc	(6	mm)	diameter,	Positive	control	zone	is	35	to	40	mm,		“‐”=	Not	active.	
	
	
Table	3	Antioxidant	activity	of	benzisoxazoles	9a‐h.	
Compounds	 IC50	values	in	µM	
DPPH	radical	Scavenging	Assay	 Hydroxyl	radical	Scavenging	assay	 Superoxide	radical	scavenging	assay	
9a	 3.8	 3.7 2.3
9b	 7.4	 7.6 5.0
9c	 4.0	 4.1 2.5
9d	 6.8	 7.0	 6.9	
9e	 8.8	 7.8	 9.4	
9f	 5.4	 5.7	 7.0	
9g	 5.2	 4.7 6.6
9h	 7.0	 6.6 4.3
Ascorbic	acid	 3.5	 3.4 2.8
	
	
	
1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	8.24	(s,	1H,	Ar‐H),	8.04	
(d,	1H,	J	=	7.8	Hz,	Ar‐H),	7.97	(d,	1H,	J	=	7.6	Hz,	Ar‐H),	7.54	(m,	
2H,	Ar‐H),	7.24	(m,	1H,	Ar‐H),	7.02	(s,	1H,	Ar‐H),	3.25‐3.36	(m,	
8H,	CH2),	2.71	(m,	1H,	CH),	2.52	(s,	3H,	CH3),	1.61‐1.83	(m,	8H,	
CH2).	MS	(ESI,	m/z):	572	(M+1).	Anal.	calcd.	for	C28H27F2N3O6S:	
C,	58.84;	H,	4.76;	N,	7.35.	Found:	C,	58.89;	H,	4.81;	N,	7.41%.		
4‐(4‐(6‐Fluorobenzo[d]isoxazol‐3‐yl)piperidine‐1‐carbonyl)‐
3‐methyl‐8‐((2‐nitrophenyl)sulfonyl)‐1‐oxa‐8‐azaspiro[4.5]dec‐
3‐en‐2‐one	 (9f):	 Colour:	 White.	 Yield:	 74%.	 M.p.:	 134‐136	 °C.	
FT‐IR	(KBr,	ν,	cm‐1):	1665	(Amide	CO	str.),	1771	(Ester	CO	str.),	
3032	(Ar.	CH	str.).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	9.02	(d,	
2H,	J	=	2.8	Hz,	Ar‐H),	8.94	(m,	2H,	Ar‐H),	7.56	(d,	1H,	J	=	7.2	Hz,	
Ar‐H),	7.33	(d,	1H,	J	=	7.2	Hz,	Ar‐H),	7.02	(s,	1H,	Ar‐H),	3.26‐3.39	
(m,	8H,	CH2),	2.72	(m,	1H,	CH),	2.49	(s,	3H,	CH3),	1.66‐1.81	(m,	
8H,	 CH2).	 MS	 (ESI,	 m/z):	 599	 (M+1).	 Anal.	 calcd.	 for	
C28H27FN4O8S:	 C,	 56.18;	 H,	 4.55;	 N,	 9.36.	 Found:	 C,	 56.26;	 H,	
4.62;	N,	9.42%.		
4‐(4‐(6‐Fluorobenzo[d]isoxazol‐3‐yl)piperidine‐1‐carbonyl)‐
3‐methyl‐8‐((4‐nitrophenyl)sulfonyl)‐1‐oxa‐8‐azaspiro[4.5]dec‐
3‐en‐2‐one	 (9g):	 Colour:	White.	 Yield:	 68%.	M.p.:	 140‐142	 °C.	
FT‐IR	(KBr,	ν,	cm‐1):	1669	(Amide	CO	str.),	1771	(Ester	CO	str.),	
3061	(Ar.	CH	str.).	 1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	8.71	(s,	
1H,	Ar‐H),	8.53	(d,	1H,	J	=	8.0	Hz,	Ar‐H),	8.43	(d,	1H,	J	=	8.0	Hz,	
Ar‐H),	7.89	(t,	1H,	J	=	7.8	Hz,	Ar‐H),	7.56	(d,	1H,	J	=	7.2	Hz,	Ar‐H),	
7.26	(d,	1H,	 J	=	7.3	Hz,	Ar‐H),	6.96	(s,	1H,	Ar‐H),	3.27‐3.42	(m,	
8H,	CH2),	2.67	(m,	1H,	CH),	2.47	(s,	3H,	CH3),	1.68‐1.82	(m,	8H,	
CH2).	MS	(ESI,	m/z):	599	(M+1).	Anal.	calcd.	for	C29H27FN4O8:	C,	
56.18;	H,	4.55;	N,	9.36.	Found:	C,	56.28;	H,	4.64;	N,	9.45%.		
8‐((4‐Chlorophenyl)sulfonyl)‐4‐(4‐(6‐fluorobenzo[d]isoxazol‐
3‐yl)piperidine‐1‐carbonyl)‐3‐methyl‐1‐oxa‐8‐azaspiro[4.5]dec‐
3‐en‐2‐one	 (9h):	 Colour:	White.	 Yield:	 79%.	M.p.:	 128‐130	 °C.	
FT‐IR	(KBr,	ν,	cm‐1):	1667	(Amide	CO	str.),	1774	(Ester	CO	str.),	
3059	(Ar.	CH	str.).	1H	NMR	(400	MHz,	CDCl3,	δ,	ppm):	7.53‐7.58	
(m,	2H,	Ar‐H),	7.19‐7.25	(m,	4H,	Ar‐H),	6.95	(s,	1H,	Ar‐H),	3.31‐
3.45	(m,	8H,	CH2),	2.71	(m,	1H,	CH),	2.53	(s,	3H,	CH3),	1.62‐1.85	
(m,	 8H,	 CH2).	 MS	 (ESI,	 m/z):	 588	 (M+1).	 Anal.	 calcd.	 for	
C28H27ClFN3O6S:	C,	 57.19;	H,	4.63;	N,	 7.15.	 Found:	 C,	 57.26;	H,	
4.69;	N,	7.21%.		
	
2.3.	Biological	evaluation‐antibacterial,	antioxidant	and	
anti‐inflammatory	activities	
	
2.3.1.	Antibacterial	activity	
	
Antibacterial	 tests	 were	 carried	 out	 by	 disc	 diffusion	
method	using	100	μL	of	suspension	containing	106	cells/mL	of	
bacteria.	The	discs	(6	mm	diameter)	were	impregnated	with	5	
mg	 and	 10	 mg/mL	 of	 each	 compound	 and	 placed	 on	 the	
inoculated	 nutrient	 agar.	 Then,	 the	 inoculated	 plates	 were	
incubated	 at	 37±0.1	 °C	 at	 24	 h.	 One	 antibacterial	 drug,	
chloramphenicol	 was	 used	 as	 positive	 control.	 Antibacterial	
activity	 was	 evaluated	 by	 measuring	 the	 zone	 of	 inhibition	
against	 the	 test	 organisms	 and	 the	 results	 are	 summarised	 in	
Table	2.	
	
2.3.2.	Antioxidant	activity	
	
2.3.2.1.	DPPH	radical	scavenging	assay	
	
DPPH	 radical	 scavenging	 assays	 [15]	 were	 performed	 in	
300	µL	reaction	mixtures	containing	200	µL	of	0.1	mM	DPPH–
ethanol	 solution,	 90	 µL	 of	 50	mM	 Tris‐HCl	 buffer	 (pH	 =	 7.4),	
and	 10	 µL	 of	 deionised	 water	 (as	 control)	 and	 various	
concentrations	 of	 compounds	9a‐h	 (1.7‐8.8	 µg/mL).	 Ascorbic	
acid	was	used	as	a	standard.	After	30	min	of	incubation	at	room	
temperature,	 absorbance	 (540	 nm)	 of	 the	 reaction	 mixtures	
was	 taken	 by	 a	 plate	 reader	 (Lab	 systems	Mullikan	MS).	 The	
percentage	radical	scavenging	activity	was	calculated	according	
to	the	following	formula:		
	
Inhibition	(%)	=	(Absorbance	control‐Absorbance	Sample/		
																																	Absorbance	Control)	×	100	 	 (1)	
	
The	 DPPH	 radical	 scavenging	 activity	 is	 demonstrated	 in	
Figure	1	and	Table	3.	
	
	
	
Figure	1. DPPH	radical	scavenging	assay.	
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Table	4.	Anti‐inflammatory	activity	of	benzisoxazoles	9a‐h	*.	
Compounds	 IC50	values	in	µM	
Lipoxygenase	inhibition	assay PLA2 inhibition	assay	
9a	 3.4	 44.0
9b	 7.8	 68.4
9c	 3.7	 50.4
9d	 9.5	 76.6	
9e	 7.8	 73.1	
9f	 4.0	 46.4	
9g	 3.7	 35.0
9h	 6.5	 56.3	
Indomethacin	 3.5	 ‐
Aristolochic	acid	 ‐	 30.0
*	“‐”=	Not	determined.	
	
	
2.3.2.2.	Hydroxyl	radical	scavenging	assay		
	
The	reaction	mixture	in	final	volume	of	2	mL	containing	0.1	
mL	of	EDTA	(1	mM),	0.01	mL	of	FeCl3	(10	mM),	0.1	mL	of	H2O2	
(10	 mM),	 0.36	 mL	 of	 deoxyribose	 (10	 mM),	 1	 mL	 of	 the	
compounds	9a‐h	(concentrations	from	1.7‐8.8	µg/mL),	0.33	mL	
of	phosphate	buffer	(50	mM,	pH	=	7.4)	and	0.1	mL	ascorbic	acid	
(1	mM)	added	in	sequence.	The	mixture	was	incubated	at	37	°C	
for	1	h.	1	mL	of	the	incubated	mixture	was	mixed	with	1	mL	of	
10%	 trichloro	 acetic	 acid	 and	 1	 mL	 of	 TBA	 (1%	 in	 0.025	 M	
NaOH),	the	resulting	mixture	was	incubated	in	water	bath	at	90	
°C	 for	 20	 min	 to	 develop	 a	 pink	 chromogen	 which	 was	
measured	at	532	nm	[16].	Ascorbic	acid	was	used	as	a	positive	
control.	 Percentage	 inhibition	 was	 evaluated	 by	 using	 the	
equation	
	
Inhibition	(%)	=	(Absorbance	control‐Absorbance	Sample/					
																																Absorbance	Control)	×	100	 	 (2)	
	
The	 potency	 of	 benzisoxazoles	 for	 hydroxyl	 radical	
scavenging	activity	is	illustrated	in	Figure	2	and	Table	3.	
	
	
	
Figure	2.	Hydroxyl	radical	scavenging	assay.
	
	
2.3.2.3.	Superoxide	anion	radical	scavenging	assay	
	
The	percentage	inhibition	of	superoxide	radical	at	1	mL	of	
NBT	(156	µM	NBT	in	100	mM	phosphate	buffer	of	pH	=	7.4),	1	
mL	of	NADH	(468	µM	in	100	mM	phosphate	buffer	of	pH	=	7.4)	
and	varying	concentration	of	compounds	9a‐h	(1.1‐5.8	µg/mL)	
were	mixed	 to	 give	 a	 final	 volume	 of	 3	mL.	 The	 reaction	was	
started	 by	 the	 addition	 of	 100	 µL	 of	 PMS	 (60	 µM	 in	 100	mM	
phosphate	 buffer	 of	 pH	 =	 7.4).	 The	 reaction	 mixture	 was	
incubated	at	25	°C	for	5	min	and	the	absorbance	was	measured	
at	 560	 nm.	 Ascorbic	 acid	 was	 used	 as	 a	 standard	 [17].	
Decreased	 absorbance	 of	 the	 reaction	 mixture	 indicated	
increased	 superoxide	 anion	 scavenging	 activity	 and	 it	 is	
illustrated	in	Figure	3	and	Table	3.	
	
2.3.3.	Anti‐inflammatory	activity	
	
2.3.3.1.	Lipoxygenase	inhibition	assay	
	
Lipoxygenase	 inhibition	 assay	 [18]	 was	 carried	 out	 using	
linoleic	acid	as	substrate	and	lipoxgenase	enzyme.	To	a	solution	
of	0.1	mL	of	2	M	borate	buffer	(pH	=	9.0),	0.1	mL	of	1000	units	
lipoxidase	 enzyme,	 solution	 of	 compounds	 9a‐h	 in	 DMSO	 (1	
mg/mL)	 was	 added	 and	 incubated	 with	 the	 enzyme	 with	
various	concentrations.	The	tubes	were	agitated	and	incubated	
at	room	temperature	for	5	min,	after	which	2.0	mL	of	substrate	
solution,	0.6	mM	linoleum	acid	were	added,	mixed	well	and	the	
absorbance	was	measured	spectrophotometrically	for	4	min	at	
234	 nm	 (Shimadzu‐2401	 PC).	 Indomethacin	 was	 used	 as	 a	
reference	 standard	 drug.	 Percentage	 (%)	 inhibition	 was	
calculated	by	the	following	equation		
	
Inhibition	(%)	=	(Absorbance	control‐Absorbance	Sample/																							
																															Absorbance	Control)	×	100	 	 (3)	
	
The	 lipoxygenase	 inhibition	 activity	 of	 benzisoxazole	 is	
summarised	in	Table	4	and	Figure	4.	
	
	
Figure	3.	Superoxide	radical	scavenging	assay.	
	
	
	
	
Figure	4. Lipoxygenase	inhibition	assay.	
	
	
2.3.3.2.	Inhibition	of	PLA2	induced	haemolysis	in	human	
erythrocytes	
	
The	substrate	for	indirect	hemolytic	activity	was	prepared	
by	suspending	1	mL	of	fresh	human	red	blood	cells	and	1	mL	of	
fresh	Hen’s	egg	yolk	in	8	mL	of	phosphate	buffered	saline.	1	mL	
of	suspension	was	incubated	with	4‐28	μg	of	partially	purified	
venom	for	45	min	at	37	°C	and	the	reaction	was	stopped	by	the	
Shivaprasad	et	al.	/	European	Journal	of	Chemistry	5	(1)	(2014)	91‐95	 95	
 
addition	 of	 9	 mL	 of	 ice	 cold	 PBS.	 The	 suspension	 was	
centrifuged	 at	 2000	 rpm	 for	 20	 min	 and	 then	 the	 released	
haemoglobin	 was	 read	 at	 540	 nm.	 10	 μg	 of	 venom	 sample	
(secretory‐PLA2	 purchased	 from	 sigma)	 was	 incubated	 with	
various	concentration	of	compounds	9a‐h	(1	mg/mL	in	DMSO)	
for	 30	mins	 at	 room	 temperature	 and	 1	mL	 of	 substrate	was	
added,	 again	 incubated	 for	 30	mins	 at	 room	 temperature	 and	
the	reaction	was	stopped	by	adding	9	mL	of	ice	cold	PBS	to	all	
test	 tubes	 and	 centrifuged	 at	 2000	 rpm	 for	 10	 mins.	 Finally	
absorbance	 was	 measured	 at	 540	 nm	 [19]	 and	 inhibitory	
activities	are	summarised	in	Table	4	and	Figure	5.	
	
	
	
Figure	5.	Inhibition	of	PLA2	induced	haemolysis.
	
	
3.	Results	and	discussion	
	
The	 key	 intermediate	 4‐(4‐(6‐fluorobenzo[d]isoxazol‐3‐yl)	
piperidine‐1‐carbonyl)‐3‐methyl‐1‐oxa‐8‐azaspiro[4.5]dec‐3‐
en‐2‐one	 hydrochloride	 7	 was	 prepared	 according	 to	 our	
earlier	 reported	 procedure	 [14].	 Thus,	 cyclocondensation	 of	
tert‐butyl	 4‐oxopiperidine‐1‐carboxylate,	 1,	 with	 dimethyl	 2‐
methylenesuccinate,	 2,	 in	 presence	 of	 sodium	 methoxide	 in	
THF	 gave	 8‐tert‐butyl	 4‐methyl	 3‐methyl‐2‐oxo‐1‐oxa‐8‐
azaspiro[4.5]dec‐3‐ene‐4,8‐dicarboxylate,	 3,	 in	 70%	 yield.	
Selective	 hydrolysis	 of	methyl	 ester	 group	 in	 compound	3	 by	
lithium	hydroxide	in	methonolic	water	was	carried	out	to	get	8‐
(tert‐butoxycarbonyl)‐3‐methyl‐2‐oxo‐1‐oxa‐8‐azaspiro[4.5]	
dec‐3‐ene‐4‐carboxylic	 acid,	4,	 in	 89%	 yield.	 Condensation	 of	
compound	4	with	6‐fluoro‐3‐(piperidin‐4‐yl)benzo[d]isoxazole	
hydrochloride,	 5,	 [20]	 in	 presence	 of	 1‐ethyl‐3‐(3‐dimethyl‐
aminopropyl)carbodiimide	 hydrochloride	 (EDC.HCl)	 and	
hydroxyl	 benzotriazole	 (HOBt)	 in	 dichloromethane	 to	 afford	
tert‐butyl	 4‐(4‐(6‐fluorobenzo[d]isoxazol‐3‐yl)piperi‐dine‐1‐
carbonyl)‐3‐methyl‐2‐oxo‐1‐oxa‐8‐azaspiro[4,5]dec‐3‐ene‐8‐
carboxylate,	6.	Cleavage	of	tert‐butyl	oxy	group	in	compound	6	
by	saturated	solution	of	hydrochloric	acid	 in	ether	 to	give	 the	
key	 intermediate	 4‐(4‐(6‐fluorobenzo[d]isoxazol‐3‐yl)piperi‐
dine‐1‐carbonyl)‐3‐methyl‐1‐oxa‐8‐azaspiro[4.5]dec‐3‐en‐2‐
one	hydrochloride,	7.	 Sulfonation	 of	 compound	7	was	 carried	
out	with	various	sulfonyl	chlorides	8	to	get	final	products	9.	
All	 compounds	 showed	 moderate	 antibacterial	 activity	
against	Escherichia	coli,	Klebsiella	pneumonia,	Salmonella	typhi	
and	 Bacillus	 subtilis.	 While	 all	 compounds	 except	 9d	 and	 9f	
were	 inactive	 against	 Shigella	 flexneri.	 Compound	9d	without	
any	 substituent	 on	 phenyl	 ring	 showed	 highest	 antibacterial	
activity.	 In	 all	 the	 anti‐oxidant	 assays	 compounds	 9a	 and	 9c	
containing	 methyl	 and	 methoxy	 substituent	 showed	 good	
inhibitory	 activity.	 The	 remaining	 compounds	 showed	
moderate	 anti‐oxidant	 activity.	 However,	 it	 is	 not	 possible	 to	
give	 any	 rational	 explanation	 for	 the	 antioxidant	 activities	 of	
these	compounds	even	in	the	absence	of	essential	enolic	group.	
In	 both	 lipoxygenase	 inhibition	 and	 PLA2	 inhibition	 assays,	
compounds	 9a	 bearing	 methyl	 group	 at	 4‐position	 of	 phenyl	
ring	and	compounds	9f	and	9g	bearing	nitro	group	at	2‐	and	4‐
position	 of	 phenyl	 ring	 respectively	 exhibited	 good	 anti‐
inflammatory	 activity,	 the	 remaining	 compounds	 showed	
moderate	activity.	
4.	Conclusion	
	
In	 summary,	 we	 have	 synthesized	 a	 new	 series	 of	
benzisoxazole	derivatives	in	good	yields	and	evaluated	for	their	
antibacterial,	 antioxidant	 and	 anti‐inflammatory	 activities.	
Benzisoxazole	 derivative	 without	 substitution	 on	 phenyl	 ring	
showed	 good	 antibacterial	 activity	 against	 Escherichia	 coli,	
Klebsiella	 pneumonia,	 Salmonella	 typhi	 and	 Bacillus	 subtilis.	
Benzisoxazoles	 9a	 and	 9c	 bearing	 methyl	 and	 methoxy	
substituents	 exhibited	 prominent	 antioxidant	 activity	 and	 9f	
and	9g	bearing	electron	withdrawing	nitro	group	showed	good	
anti‐inflammatory	 activity.	 Thus	 a	 new	 class	 of	 benzisoxazole	
derivatives	 can	 be	 incorporated	 to	 the	 family	 of	 bioactive	
heterocyclic	compounds.	It	should	also	be	noted	that,	in	general	
compounds	 bearing	 activating	 groups	 on	 phenyl	 ring	 showed	
good	antioxidant	activities,	and	those	with	deactivating	groups	
exhibited	anti‐inflammatory	activities.		
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